MiMedx Group, Inc (NASDAQ:MDXG) Given Consensus Rating of “Moderate Buy” by Analysts

MiMedx Group, Inc (NASDAQ:MDXG) has been given a consensus rating of “Moderate Buy” by the seven brokerages that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $8.50.

A number of equities analysts have weighed in on MDXG shares. Wall Street Zen cut shares of MiMedx Group from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Weiss Ratings downgraded MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th. Craig Hallum reduced their price target on MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a report on Friday, April 17th. Finally, Citizens Jmp lowered their price objective on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research note on Thursday, April 30th.

MiMedx Group Trading Down 3.1%

NASDAQ MDXG opened at $4.23 on Thursday. The company’s fifty day simple moving average is $3.90 and its 200-day simple moving average is $4.25. MiMedx Group has a 52 week low of $3.03 and a 52 week high of $7.99. The company has a current ratio of 5.39, a quick ratio of 4.81 and a debt-to-equity ratio of 0.07. The stock has a market cap of $629.61 million, a P/E ratio of 21.14 and a beta of 1.45.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.02). MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. The firm had revenue of $64.36 million during the quarter, compared to analysts’ expectations of $63.46 million. Equities research analysts predict that MiMedx Group will post -0.09 EPS for the current fiscal year.

Institutional Trading of MiMedx Group

Hedge funds have recently made changes to their positions in the stock. Nantahala Capital Management LLC acquired a new stake in MiMedx Group in the third quarter valued at $10,237,000. Marshall Wace LLP increased its position in shares of MiMedx Group by 864.9% in the 4th quarter. Marshall Wace LLP now owns 1,381,288 shares of the company’s stock worth $9,351,000 after purchasing an additional 1,238,132 shares during the last quarter. Hillsdale Investment Management Inc. bought a new stake in shares of MiMedx Group in the 4th quarter worth about $7,134,000. Disciplined Growth Investors Inc. MN raised its stake in shares of MiMedx Group by 283.0% in the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company’s stock valued at $9,656,000 after purchasing an additional 1,022,202 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY raised its stake in shares of MiMedx Group by 39.1% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 3,410,300 shares of the company’s stock valued at $13,471,000 after purchasing an additional 959,100 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.